Analyst Activity – BMO Capital Markets Lowers Its Price Target On Five Prime Therapeutics (NASDAQ:FPRX) to

ME Staff
-
0

Analyst Ratings For Five Prime Therapeutics (NASDAQ:FPRX)

Today, BMO Capital Markets lowered its price target on Five Prime Therapeutics (NASDAQ:FPRX) to per share.

Some recent analyst ratings include

  • 9/12/2017-Jefferies Group Reiterated Rating of Buy.
  • 3/24/2017-Cowen initiated coverage with a Outperform rating.
  • 3/1/2017-Instinet initiated coverage with a Buy rating.
  • 11/7/2016-Credit Suisse Group Reiterated Rating of Buy.

Recent Insider Trading Activity For Five Prime Therapeutics (NASDAQ:FPRX)
Five Prime Therapeutics (NASDAQ:FPRX) has insider ownership of 6.50% and institutional ownership of 73.98%.

  • On 11/1/2017 William R Ringo, Director, sold 600 with an average share price of $45.33 per share and the total transaction amounting to $27,198.00.
  • On 10/2/2017 William R Ringo, Director, sold 1,800 with an average share price of $40.26 per share and the total transaction amounting to $72,468.00.
  • On 9/28/2017 William R Ringo, Director, sold 2,000 with an average share price of $38.00 per share and the total transaction amounting to $76,000.00.
  • On 3/1/2017 William R Ringo, Director, sold 500 with an average share price of $46.73 per share and the total transaction amounting to $23,365.00.
  • On 2/1/2017 William R Ringo, Director, sold 500 with an average share price of $46.17 per share and the total transaction amounting to $23,085.00.
  • On 1/18/2017 Francis Willard Sarena, Insider, sold 3,636 with an average share price of $47.39 per share and the total transaction amounting to $172,310.04.
  • On 1/3/2017 William R Ringo, Director, sold 500 with an average share price of $51.07 per share and the total transaction amounting to $25,535.00.

Recent Trading Activity for Five Prime Therapeutics (NASDAQ:FPRX)
Shares of Five Prime Therapeutics closed the previous trading session at 22.55 up +3.97 21.37% with 18.829999923706055 shares trading hands.